Once again in March, the pharmaceutical world saw a series of notable hires. From biotech to pharma, companies are strengthening their teams with experienced professionals.
For the digital health and pharma suppliers we cover, February was a month of changes, with CEOs coming and going (sometimes dramatically), and several other C-Suite and board shake-ups.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh